BCLI Overview

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.

Wall Street analysts forecast BCLI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCLI is6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Brainstorm Cell Therapeutics Inc revenue for the last quarter amounts to -3.09M USD, increased 24.86

Brainstorm Cell Therapeutics Inc. EPS for the last quarter amounts to USD, decreased -100.00

Brainstorm Cell Therapeutics Inc (BCLI) has 27 emplpoyees as of May 31 2026.

Today BCLI has the market capitalization of 24.63M USD.